Compare IPCA Labs with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TORRENT PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS TORRENT PHARMA IPCA LABS/
TORRENT PHARMA
 
P/E (TTM) x 23.2 37.0 62.8% View Chart
P/BV x 8.3 9.4 88.7% View Chart
Dividend Yield % 0.1 0.6 22.4%  

Financials

 IPCA LABS   TORRENT PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
TORRENT PHARMA
Mar-19
IPCA LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0421,964 53.1%   
Low Rs5901,245 47.4%   
Sales per share (Unadj.) Rs298.6453.4 65.9%  
Earnings per share (Unadj.) Rs35.025.8 135.7%  
Cash flow per share (Unadj.) Rs49.462.3 79.4%  
Dividends per share (Unadj.) Rs3.0017.00 17.6%  
Dividend yield (eoy) %0.41.1 34.7%  
Book value per share (Unadj.) Rs247.1279.2 88.5%  
Shares outstanding (eoy) m126.35169.22 74.7%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.73.5 77.2%   
Avg P/E ratio x23.362.2 37.5%  
P/CF ratio (eoy) x16.525.8 64.1%  
Price / Book Value ratio x3.35.7 57.5%  
Dividend payout %8.665.9 13.0%   
Avg Mkt Cap Rs m103,108271,513 38.0%   
No. of employees `00013.413.6 98.9%   
Total wages/salary Rs m7,87414,038 56.1%   
Avg. sales/employee Rs Th2,807.05,642.6 49.7%   
Avg. wages/employee Rs Th585.81,032.4 56.7%   
Avg. net profit/employee Rs Th329.0320.9 102.5%   
INCOME DATA
Net Sales Rs m37,73276,728 49.2%  
Other income Rs m577571 101.1%   
Total revenues Rs m38,30977,299 49.6%   
Gross profit Rs m6,90119,831 34.8%  
Depreciation Rs m1,8246,177 29.5%   
Interest Rs m1895,038 3.7%   
Profit before tax Rs m5,4659,187 59.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m1,0421,254 83.2%   
Profit after tax Rs m4,4224,363 101.4%  
Gross profit margin %18.325.8 70.8%  
Effective tax rate %19.113.6 139.8%   
Net profit margin %11.75.7 206.1%  
BALANCE SHEET DATA
Current assets Rs m23,77850,375 47.2%   
Current liabilities Rs m10,97551,653 21.2%   
Net working cap to sales %33.9-1.7 -2,037.4%  
Current ratio x2.21.0 222.1%  
Inventory Days Days10492 112.7%  
Debtors Days Days6668 96.5%  
Net fixed assets Rs m20,36883,648 24.3%   
Share capital Rs m253846 29.9%   
"Free" reserves Rs m30,97146,397 66.8%   
Net worth Rs m31,22447,244 66.1%   
Long term debt Rs m1,40939,129 3.6%   
Total assets Rs m45,507141,209 32.2%  
Interest coverage x30.02.8 1,061.0%   
Debt to equity ratio x00.8 5.4%  
Sales to assets ratio x0.80.5 152.6%   
Return on assets %10.16.7 152.2%  
Return on equity %14.29.2 153.4%  
Return on capital %17.312.3 140.4%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30822,103 78.3%   
Fx outflow Rs m6,2665,522 113.5%   
Net fx Rs m11,04216,581 66.6%   
CASH FLOW
From Operations Rs m4,92317,981 27.4%  
From Investments Rs m-1,563-2,413 64.8%  
From Financial Activity Rs m-1,832-13,145 13.9%  
Net Cashflow Rs m1,5282,380 64.2%  

Share Holding

Indian Promoters % 45.9 71.5 64.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 7.0 162.4%  
FIIs % 25.3 12.6 200.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.8 197.7%  
Shareholders   36,892 26,511 139.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  CIPLA  JUBILANT PHARMOVA   

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 7, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS